Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - toxoid tat-tetnu - immunoloġiċi għall-equidae - Żwiemel - immunizzazzjoni attiva ta 'żwiemel li għandhom età ta' 6 xhur kontra t-tetnu biex tevita l-mortalità. bidu ta 'immunità: 2 ġimgħat wara l-vaċċinazzjoni primarja courseduration ta' l-immunità: 17-il xahar wara l-ewwel kors ta ' tilqim, 24 xahar wara l-ewwel revaċċinazzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - trattament sintomatiku ta 'dimenzja ta' alzheimer ħafifa għal moderatament gravi. kura sintomatika ta 'minn ħafifa għal moderatament gravi dimenzja f'pazjenti bil-marda idjopatika ta' parkinson.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

corza medical gmbh - fibrinoġen uman, trombina umana - hemostasi, kirurġiċi - sustanzi kontra l-emorraġija - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicin hydrochloride - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - aġenti antineoplastiċi - caelyx liposomali pegilat huwa indikat:bħala monoterapija għal pazjenti b'kanċer tas-sider metastatiku, fejn hemm żieda ta 'riskju kardijaċi;għall-kura avvanzata ta' l-ovarji f'nisa li jkunu fallew l-ewwel linja bbażata fuq il-platinu 'kors ta' kimoterapija;flimkien ma 'bortezomib għall-kura tal-mjeloma multipla progressiva f'pazjenti li rċevew mill-anqas terapija waħda qabel u li diġà għaddew jew li mhumiex tajbin għal trapjant tal-mudullun;għat-trattament tal-aids marbuta mal-sarkoma ta'kaposi (ks) f'pazjenti b'għadd ta' cd4 baxx (.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - doxorubicin hydrochloride - neoplażmi tas-sider - aġenti antineoplastiċi - myocet doxorubicin, f'kombinazzjoni ma 'cyclophosphamide, huwa indikat għall-kura preferita ta' kanċer metastatiku tas-sider f'nisa adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bracco international b.v. - hexafluworidu tal-kubrit - ultrasonography; echocardiography - midja ta 'kuntrast - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. sonovue hu għall-użu mal-viżjoni bl-ultrasawnd biex itejbu l-echogenicity tad-demm, jew ta ' fluwidi fil-apparat tal-awrina li jirriżulta f'titjib signal to noise ratio. sonovue għandu jintuża biss f'pazjenti fejn l-istudju mingħajr titjib tal-kuntrast ikun inkonklussiv. echocardiographysonovue huwa tal-kuntrast ekokardjografiku transpulmonari għall-użu f'pazjenti adulti b'suspett jew stabbilita mard kardjovaskulari biex jipprovdu opacification tal-kmamar tal-qalb u jsaħħaħ-ventrikolu tax-xellug endocardial-delineazzjoni tal-fruntiera. doppler tal-macrovasculaturesonovue iżid il-preċiżjoni fil-kxif jew l-esklużjoni ta ' anormalitajiet fl-arterji ċerebrali u extracranial karotide jew fl-arterji periferali f'pazjenti adulti billi jtejbu l-doppler signal to noise ratio. sonovue jżid il-kwalità tal-doppler tal-fluss tal-immaġni u l-tul tal-klinikament utli titjib tas-sinjal fl-evalwazzjoni tal-vina portali f'pazjenti adulti. doppler tal-microvasculaturesonovue itejjeb il-wiri tal-vaskularità tal-fwied u fis-sider feriti waqt il-doppler sonography f'pazjenti adulti li jwassal għal karatterizzazzjoni aktar speċifika tal-leżjonijiet. ultrasonografija tal-ħmieġ ta'l-imsaren fl-awrina tractsonovue huwa indikat għall-użu fil-ultrasonografija tal-ħmieġ ta'l-imsaren fl-apparat f'pazjenti pedjatriċi mill-tarbija tat-twelid sa 18-il sena li jiġi lokalizzat vesicoureteral rifluss. għal-limitazzjoni fl-interpretazzjoni ta negattiv urosonography.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - spondylolisthesis - drogi għat-trattament ta 'mard tal-għadam - opgenra huwa indikat għal fużjoni spinali laterali posterolaterali f'pazjenti adulti bi spondylolistshes fejn l-awtograft naqas jew huwa kontra-indikat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.